Antibody Treatment of Toxin Poisoning Recent Advances

References

• Smith T W, Haber E, Yeatman L, Butler V P. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294: 797–800
   PubMed Web of Science ®Google Scholar
• Hickey A R, Wenger T L, Carpenter V P, et al. Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17: 590–598
   PubMed Web of Science ®Google Scholar
• Scherrmann J M, Terrien N, Urtizberea M, Pierson P, Denis H, Bourre J M. Immunotoxicotherapy: present status and future trends. J Toxicol Clin Toxicol 1989; 27: 1–35
   PubMedGoogle Scholar
• Ziegler E J, Fisher C J, Sprung C L, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324: 429–436
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock H W, Reiter C, Trenkmann J, Futterer A, Riethmuller G. Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes of the toxin molecule. Hybridoma 1986; 5: 21–30
   PubMed Web of Science ®Google Scholar
• Audebert F, Urtizberea M, Sabouraud A, Scherrmann J M, Bon C. Pharmacokinetics of Vipera Aspis venom after experimental envenomation in rabbits. J Pharmacol Exp Ther, (in press)
   Web of Science ®Google Scholar
• Smith T W, Butler V P, Haber E. Characterization of antibodies of high affinity and specificity for the digitalis glycoside digoxin. Biochemistry 1970; 9: 331–337
   PubMed Web of Science ®Google Scholar
• Sabouraud A, Urtizberea M, Grandgeorge M, Gattel P, Makula M E, Scherrmann J M. Dose-dependent reversal of acute murine colchicine poisoning by goat colchicine-specific Fab fragments. Toxicol 1991; 68: 121–132
   PubMed Web of Science ®Google Scholar
• Huston J S, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci 1988; 85: 5879–5883
   PubMed Web of Science ®Google Scholar
• Anthony J, Near R, Wong S L, et al. Production of stable anti-digoxin Fv in Escherichia coli. Mol Immun 1992; 29: 1237–1247
   PubMed Web of Science ®Google Scholar
• Thanh-Barthet C V, Urtizberea M, Sabouraud A E, Cano N J, Scherrmann J M. Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans. Pharm Res 1993; 10: 692–696
   PubMed Web of Science ®Google Scholar
• Covell D G, Barbet J, Holton O D, Black C D, Parker R J, Weinstein J N. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. Cancer Res 1986; 46: 3969–3978
   PubMed Web of Science ®Google Scholar
• Berry M J, Davies J. Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. J Chromatogr 1992; 597: 239–245
   PubMed Web of Science ®Google Scholar
• Urtizberea M, Latour M, Edelman L, Carcagne J, Armand J, Scherrmann J M. Immunopharmacological activity of monoclonal antidigitoxin. Dev Biol Stand 1990; 71: 147–157
   PubMedGoogle Scholar
• Pentel P R, Keyler D E, Brunn G J, et al. Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship. Drug Metab Dispos 1991; 19: 24–28
   PubMed Web of Science ®Google Scholar
• Chappey O N, Sandouk P, Scherrmann J M. Monoclonal antibodies in hapten immunoassays. Pharm Res 1992; 9: 1375–1379
   PubMed Web of Science ®Google Scholar
• Pond S M, Pentel P R, Keyler D E, Winzor D J. Determination of the in vivo antigen-antibody affinity constant from the redistribution of desipramine in rats following administration of a desipramine-specific monoclonal antibody. Biochem Pharmacol 1991; 41: 473–476
   PubMed Web of Science ®Google Scholar
• Wright A F, Green T P, Robson R T, Niewola Z, Wyatt I, Smith L L. Specific polyclonal and monoclonal antibody prevents paraquat accumulation into rat lung slices. Biochem Pharmacol 1987; 36: 1325–1331
   PubMed Web of Science ®Google Scholar
• Hunter K W, Brimfield A A, Knower A T, Powell J A, Feuerstein G Z. Reversal of intracellular toxicity of the trichothecene mycotoxin T-2 with monoclonal antibody. J Pharmacol Exp Ther 1990; 255: 1183–1187
   PubMed Web of Science ®Google Scholar
• Schmidt T A, Kjeldsen K. Enhanced clearance of specifically bound digoxin from human myocardial and skeletal muscle samples by specific digoxin antibody fragments - subsequent complete digitalis glycoside receptor (Na, K-ATPase) quantification. J Cardiovasc Pharmacol 1991; 17: 670–677
   PubMed Web of Science ®Google Scholar
• Hastie S B. Interactions of colchicine with tubulin. Pharmacol Ther 1991; 51: 377–401
   PubMed Web of Science ®Google Scholar
• Scherrmann J M, Sabouraud A, Urtizberea M, et al. Clinical use of colchicine specific Fab fragments in colchicine poisoning. Vet Hum Toxicol 1992; 34: 334
   Google Scholar
• Timsina M P, Hewick D S. The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit. J Pharm Pharmacol 1992; 44: 796–800
   PubMed Web of Science ®Google Scholar
• Owens S M, Mayersohn M. Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 1986; 14: 52–58
   PubMed Web of Science ®Google Scholar
• Hursting M J, Opheim K E, Raisys V A, et al. Tricyclic antidepressant-specific Fab fragments alter the distribution and elimination of desipramine in the rabbit: a model for overdose treatment. J Toxicol Clin Toxicol 1989; 27: 53–66
   PubMed Web of Science ®Google Scholar
• Butler V P, Schmidt D H, Smith T W, et al. Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs. J Clin Invest 1977; 59: 345–359
   PubMed Web of Science ®Google Scholar
• Sabouraud A E, Urtizberea M, Cano N J, Grandgeorge M, Rouzioux J M, Scherrmann J M. Colchicine-specific Fab fragments alter colchicine disposition in rabbits. J Pharmacol Exp Ther 1992; 260: 1214–1219
   PubMed Web of Science ®Google Scholar
• Timsina M P, Hewick D S. Digoxin-specific Fab fragments impair renal function in the rabbit. J Pharm Pharmacol 1992; 44: 867–869
   PubMed Web of Science ®Google Scholar
• Smith T W. Review of clinical experience with digoxin Fab (Ovine). Am J Emerg Med 1991; 9(Suppl 1)1–6
   PubMedGoogle Scholar
• Sabouraud A, Urtizberea M, Benmoussa K, Cano N J, Scherrmann J M. Fab-bound colchicine appears to adopt Fab fragment disposition in rats. J Pharm Pharmacol 1992; 44: 1015–1019
   PubMed Web of Science ®Google Scholar
• Hopf U, Meyer-zum-Buschenfelde K H, Dierich M P. Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol 1976; 117: 639–645
   PubMed Web of Science ®Google Scholar
• Jones P L, Brown B A, Sands H. Uptake and metabolism of 111In-labeled monoclonal antibody B6.2 by the rat liver. Cancer Res 1990; 50: 852–856
   PubMed Web of Science ®Google Scholar
• Finbloom D S, Magilavy D B, Harford J B, Rifai A, Plotz P H. Influence of antigen on immune complex behavior in mice. J Clin Invest 1981; 68: 214–224
   PubMed Web of Science ®Google Scholar
• Martiny S S, Phelps S J, Massey K L. Treatment of severe digitalis intoxication with digoxin-specific antibody fragments—a clinical review. Crit Care Med 1988; 16: 629–635
   PubMed Web of Science ®Google Scholar
• Brunn G J, Keyler D E, Pond S M, Pentel P R. Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: effects on hypotension and interaction with sodium bicarbonate. J Pharmacol Exp Ther 1992; 260: 1392–1399
   PubMed Web of Science ®Google Scholar
• Terrien N, Urtizberea M, Scherrmann J M. Reversal of advanced colchicine toxicity in mice with goat colchicine-specific antibodies. Toxicol Appl Pharmacol 1990; 104: 504–510
   PubMed Web of Science ®Google Scholar
• Stead A H, Moffat A C. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Human Toxicol 1983; 2: 437–464
   PubMedGoogle Scholar
• Pluckthun A. Antibodies from Escherichia coli. Nature 1990; 347: 497–498
   PubMed Web of Science ®Google Scholar
• Callaghan T A, Fleetwood P, Contreras M, Molisson P L, Scherrmann J M. Human monoclonal anti-D with a normal half-life. Transfusion 1993; 33: 784–785
   PubMed Web of Science ®Google Scholar
• Perez N, Le Deist F, Chatenoud L, Chanteloup N, Griscelli C, Fischer A. In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. Bone Marrow Transplant 1989; 4: 379–384
   PubMed Web of Science ®Google Scholar